What You Should Know:
– Elucent Medical, a leader in surgical navigation with its In-Site Spatial Intelligence (iSI) technology raises $42.5M in Series C funding, led by Vensana Capital and RC Capital with participation from existing investors.
– This significant investment will fuel the development and commercialization of Elucent’s innovative EnVisio® and SmartClip® technologies, designed to improve precision and effectiveness in cancer surgery.
Pioneering In-Site Spatial Intelligence
Elucent’s flagship technologies, EnVisio® and SmartClip®, provide surgeons with real-time, in-situ (within the body) spatial intelligence during critical operations. EnVisio® utilizes proprietary technology to transform standard surgical instruments into “smart” tools. These smart tools can be tracked in real-time and guided with millimeter precision, enabling surgeons to operate with greater accuracy.
EnVisio®: Beyond Breast Cancer
While EnVisio® is currently optimized for breast cancer surgery, its platform is expanding to address other soft-tissue oncology procedures. Elucent is also developing additional products using the iSI platform to assist surgeons in achieving margin-negative resections (complete removal of cancerous tissue) in lung and other soft tissue surgeries. These new products seamlessly integrate with existing surgical tools and minimally invasive solutions, including video-assisted and robotic-assisted surgical technologies.
“We are proud to have secured this substantial funding, which will advance our mission to radically change the way surgeons mark and locate their intended target for removal by turning their existing surgical instruments into intelligent tracking devices that elevate the standard of care in soft tissue oncologic procedures,” says Jason Pesterfield, President and CEO of Elucent Medical. “With the support of our investors, we are poised to accelerate the commercialization of our EnVisio® and SmartClip® technologies, empowering healthcare providers with innovative tools to improve patient outcomes.”
